rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    MYGN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Stephens raises Myriad Genetics stock price target on revenue beat
      Nov 12Investing.comMYGN
      Myriad Genetics’s Q3 2026 earnings call: our top 5 analyst questions
      Nov 8Yahoo FinanceMYGN
      Myriad Genetics reports unauthorized access to IT network, resumes most operations
      Nov 5Investing.comMYGN
      Myriad Genetics Inc (MYGN) Q3 2026 Earnings Call Highlights: Revenue Guidance Raised as ...
      Nov 5Yahoo FinanceMYGN
      Myriad Genetics earnings beat by $0.09, revenue topped estimates
      Nov 5Investing.comMYGN
      Myriad Genetics (MYGN) Reports Q3 Loss, Beats Revenue Estimates
      Nov 4Yahoo FinanceMYGN
      Myriad Genetics Q3 Earnings Call Highlights
      Nov 4Yahoo FinanceMYGN
      Myriad Genetics Q3 2026 Earnings Call Transcript
      Nov 4BenzingaMYGN
      Myriad Genetics (NASDAQ:MYGN) reports upbeat Q3 2026, stock jumps 10.7%
      Nov 4Yahoo FinanceMYGN
      Myriad Genetics presents data on cancer recurrence detection test
      Oct 22Investing.comMYGN
      Myriad Genetics (MYGN) Stock Sees Fair Value Lift After Split Analyst Revisions
      Oct 22Yahoo FinanceMYGN
      Myriad Genetics: Prenatal Sale Provides A Lifeline In A Tough Spot (NASDAQ:MYGN)

      Myriad Genetics sells its prenatal testing business to boost liquidity, but losses persist. Click here to read this latest analysis of MYGN stock.

      Oct 22Seeking AlphaMYGN
      Labcorp to buy Myriad’s prenatal health testing unit for $210M
      Oct 22Yahoo FinanceMYGNLH
      Myriad Genetics Says New Results Show Potential of MRD Detection in Colorectal, Pancreatic Cancers
      Oct 22Yahoo FinanceMYGN
      Stocks making big moves yesterday: Washington Trust Bancorp, Doximity, Myriad Genetics, Arhaus, and Gartner
      Oct 21Yahoo FinanceMYGNWASH
      Myriad Genetics (MYGN) Stock Trades Up, Here Is Why
      Oct 20Yahoo FinanceMYGN
      TD Cowen holds Myriad Genetics stock rating on Labcorp sale
      Oct 20Investing.comMYGNLH
      12 Health Care Stocks Moving In Tuesday's Intraday Session
      Oct 20BenzingaMYGN
      Why Is Myriad Genetics Stock Trading Higher Today? - Myriad Genetics (NASDAQ:MYGN)
      Oct 20BenzingaMYGNLH
      Myriad Genetics stock surges on $210M prenatal unit sale
      Oct 20Investing.comMYGN
      Hasbro Posts Upbeat Q3 Earnings, Joins Myriad Genetics, Equifax And Other Big Stocks Moving Higher On Tuesday
      Oct 20BenzingaHASMYGNEFX
      Myriad to sell prenatal health business to Labcorp (MYGN:NASDAQ)
      Oct 20Seeking AlphaMYGNLH
      Why is Myriad Genetics stock surging today?
      Oct 20Investing.comMYGN
      Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
      Oct 20Yahoo FinanceMYGNLH
      Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know
      Oct 16Yahoo FinanceAZTAMYGNRGEN
      Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
      Oct 15Yahoo FinanceMYGN
      What Myriad Genetics Doubters Saw Before The Drop
      Oct 14Yahoo FinanceMYGN
      Myriad, SOPHiA partner with AstraZeneca to use prostate cancer technology

      Myriad and SOPHiA partner with AstraZeneca to apply PrGIS genomic instability scoring in prostate cancer trials, advancing HRD companion diagnostics. Read more here.

      Oct 8Seeking AlphaAZNMYGNSOPH
      Myriad Genetics, SOPHiA partner on prostate cancer biomarker
      Oct 8Investing.comMYGNSOPH
      Myriad Genetics (MYGN) Stock Sees Fair Value Lift As Analysts Weigh Split Targets

      The recent update to fair value, from US$3.37 to US$3.91 per share for Myriad Genetics, reflects a recalibration of what analysts think the stock could be worth. This shift sits alongside Street price targets that range widely from US$2 to US$8, with ratings spread from Underweight to Buy, which leaves you with a broad spectrum of risk and return views to consider. As you read on, you will see how these moving targets shape the evolving Myriad Genetics story and what to watch next. Stay...

      Oct 4Yahoo FinanceMYGN
      Why Is Myriad Genetics (MYGN) Stock Soaring Today
      Oct 3Yahoo FinanceMYGN
      Myriad Genetics (MYGN) Stock Fair Value Moves Lower After Analyst Cuts And Guidance Reset

      Myriad Genetics is back in focus after a sharp reset in analyst price targets, with the modelled fair value estimate moving from about US$6.25 to roughly US$3.37, a cut of close to 46%. The shift lines up with more cautious Street commentary that concentrates on execution risk, profitability, and the impact of reduced FY26 guidance on how the stock is valued. As you read on, you will see how to interpret these updates and how to follow the evolving narrative around Myriad Genetics. Stay...

      Sep 18Yahoo FinanceMYGN
      1 Unpopular Stock That Deserves Some Love and 2 We Turn Down

      Detailed price information for Mckesson Corp (MCK-N) from The Globe and Mail including charting and trades.

      Sep 17The Globe and MailMYGN
      Myriad Genetics promotes Vishal Sikri to commercial chief
      Sep 16Investing.comMYGN
      Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial

      SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promoted to Executive Vice President - Commercial, effective September 16, 2026. Vishal has served as the SVP of Product at Myriad for the past year. He has deep understanding of molecular diagnostics and oncology as well as extensive business and commercial leadership experience from his prior roles

      Sep 16Yahoo FinanceMYGN
      2 Unprofitable Stocks to Research Further and 1 We Find Risky

      Detailed price information for Blink Charging Company (BLNK-Q) from The Globe and Mail including charting and trades.

      Sep 15The Globe and MailMYGN
      Myriad Genetics at Wells Fargo conference: cancer focus amid pressure
      Sep 10Investing.comMYGN
      UBS Adjusts Price Target on Myriad Genetics to $3.60 From $6, Keeps Neutral Rating

      Myriad Genetics (MYGN) has an average rating of hold and mean price target of $3.37, according to an

      Sep 9Yahoo FinanceMYGN
      Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)

      Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers.

      Sep 8Yahoo FinanceMYGN
      Stocks making big moves yesterday: Myriad Genetics, Greenbrier, Tidewater, Strategy, and Charter

      Check out the companies making headlines yesterday:

      Sep 2Yahoo FinanceMYGNGBXTDW
      Why Myriad Genetics (MYGN) Stock Is Down Today

      Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 6.2% in the afternoon session after Piper Sandler double-downgraded the stock to Underweight, stating that major strategic action is likely needed.

      Sep 1Yahoo FinanceMYGN
      Myriad Genetics stock downgraded at Piper Sandler (MYGN:NASDAQ)
      Sep 1Seeking AlphaMYGNPIPR
      Myriad Genetics Stock Gets Double-Downgrade as Profitability Concerns Grow
      Sep 1Barron'sMYGN
      Myriad Genetics shares fall 7.1% after Piper Sandler downgrade

      Myriad Genetics (NASDAQ:MYGN) shares fell 7. 1% in pre-market trading to $2.

      Sep 1Yahoo FinanceMYGNPIPR
      Why is Myriad Genetics stock tumbling today?
      Sep 1Investing.comMYGN
      Piper Sandler cuts Myriad Genetics stock rating on profit concerns
      Sep 1Investing.comMYGN
      Piper Sandler Downgrades Myriad Genetics to Underweight From Overweight
      Sep 1Yahoo FinanceMYGN
      Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference

      SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026 at 11:00am EST. The presentation will be available through a live audio webcast link in the investor information section of Myriad’s website at investor.myriad.com. About Myriad Genetics Myriad Genetics is

      Aug 27Yahoo FinanceMYGNWFC
      Myriad Genetics and Moderna Shares Plummet, What You Need To Know

      A number of stocks fell in the afternoon session after shares across biotech and big pharma cooled further as traders continued to secure profits following the extraordinary run. The sector had jumped after Phase 3 results for Moderna’s individualized neoantigen mRNA therapy, intismeran, used with Merck’s Keytruda — the first positive late-stage readout for an mRNA-based cancer vaccine over Keytruda alone. With no fresh clinical or regulatory catalyst to extend the advance, the tape has shifted

      Aug 24Yahoo FinanceMRNAMYGN

      This is the newest page. Registered accounts read further back.